Company: CNTB
Filing Date: 2025-07-21
Form Type: 8-K
Source: 0001835268-25-000044
Chunk: 0

Company: Connect Biopharma Holdings Ltd
Filing Date: 2025-07-21
Form: 8-K
Item: Item 1.02
Chunk 0
---
Item 1.02 Termination of a Material Definitive Agreement.

On July 18, 2025, Connect Biopharma Holdings Limited (the “ Company”) instructed Deutsche Bank Trust Company Americas (the “ Depositary”) to terminate the Deposit Agreement dated March 18, 2021, as amended, by and among the Company, the Depositary and the holders and beneficial owners from time to time of American Depositary Shares (the “ ADSs”), each of which represents one ordinary share, US$0.000174 par value, of the Company (each, an “ Ordinary Share”), and which are evidenced by American Depositary Receipts (the “ ADRs”) issued thereunder (the “ Deposit Agreement”). The Deposit Agreement governs the rights and obligations of the Depositary, the Company and the holders and beneficial owners of the Company’s ADSs evidenced by ADRs with respect to the listing of the Company’s ADSs on the Nasdaq Global Market (“ Nasdaq”). The ADR program and the Deposit Agreement are expected to terminate on or about September 2, 2025. At such time, the Company’s ADRs will be mandatorily cancelled and exchanged for Ordinary Shares at a one-for-one ratio.

The Depositary will distribute to all holders and beneficial owners of ADSs a notification regarding the termination of the ADR program pursuant to the Deposit Agreement. Immediately following the termination of the ADR program, the Company plans to list its Ordinary Shares directly on Nasdaq in substitution for its ADSs (the “ Substitution Listing”). The Company expects that, upon effectiveness of the Substitution Listing, its ADSs will cease to be listed on Nasdaq and the Ordinary Shares represented by the ADRs will commence trading on Nasdaq under the Company’s existing symbol “ CNTB”.

On July 21, 2025, the Company issued a press release announcing its plans to terminate the ADR program and the Deposit Agreement and to effect the Substitution Listing.

Forward-Looking Statements

This disclosure contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended (the “ Act”). Forward-looking statements are statements that are not of historical fact and include, without limitation, statements regarding the timing of the termination of the ADR program and the Deposit Agreement, as well as the Substitution Listing; and the timing of the Depositary’s delivery of the notice of termination of the ADR program pursuant to the Deposit Agreement. These statements are